GlaxoSmithKline Consumer Nigeria Plc was incorporated in Nigeria on 23rd June 1971 and commenced business on 1st July 1972, under the name Beecham Limited. The Company was quoted on the Nigerian Stock Exchange in 1977.
GlaxoSmithKline Consumer Nigeria Plc is a Nigeria-based research-based pharmaceutical and healthcare company. The principal activities of the Company are manufacturing, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's operating segments include Pharmaceuticals and Consumer Healthcare. The Consumer Healthcare segment includes oral care, over-the-counter (OTC) medicines and nutritional healthcare. The Pharmaceuticals segment consists of antibacterial, vaccines and prescription drugs. The Company offers Consumer Healthcare brands, such as Panadol, Andrews Liver Salt, Macleans, Otrivin, Sensodyne, Voltaren and a range of pharmaceuticals, including Ampiclox, Amoxil, Augmentin, Zentel, Halfan and vaccines. Global Manufacturing and Supply (GMS) is the manufacturing unit of the Company located in Agbara, Ogun State.
BOARD OF DIRECTOR
Mr Edmund C. Onuzo -Chairman
Mr Kunle Oyelana- Managing Director
Mr. Samuel Kuye – non-executive Director
Mr.Mark pfister – executive director
Mr Bosco Kirugi – finance director
Mrs Oludewa Edodo-Thorpe- non-executive director
Mr.Oussama Abass – non-executive director
1 Industrial Avenue Ilupeju Lagos Nigeria.
Phone: +23412711000
Please login to give a review.
In a positive start to the first trading day of September 2023, the Nigerian equities market displayed bullish momentum, affirming investor confidence...
The market capitalisation of the Nigerian Stock Exchange (NSE), which closed the day at N35,540 trillion, decreased by N15 billion (0.04%) as a result...
British multinational consumer goods giant Unilever has informed the investing public that it approached GlaxoSmithKline about buying the consumer goo...
At the close of business on Friday, November 12, 2021, the ASI ended trading with a 43,253.01 basis point which represented a -0.68% fall from its pre...
GlaxoSmithKline recorded a significant decline in earnings in the first half of the year, as its profit after tax for the period was N59.91 million, a...
GlaxoSmithKline recorded a significant decline in earnings in the first half of the year, as its profit after tax for the period was N59.91 million, a...
The Nigerian Stock Exchange (NSE) market closed with 4,016.00 deals on Thursday, March 25th, 2021, lower than the 4,018.00 deals on Wednesday, March 2...
The Nigerian Stock Exchange (NSE) market closed with 2,889 deals on Wednesday, November 4, 2020, lower than the 5,575 deals it closed with on Tuesday,...
GlaxoSmithKline reported revenue growth for the third quarter of 2020, as the Pharmaceutical company was able to reduce its cost of production du...
GlaxoSmithKline reported revenue growth for the third quarter of 2020, as the Pharmaceutical company was able to reduce its cost of production du...
GlaxoSmithKline reported revenue growth for the third quarter of 2020, as the Pharmaceutical company was able to reduce its cost of production du...
The Nigerian Stock Exchange market closed with 3,375 deals on Thursday, October 22, 2020, lower than the 4,367 deals it closed with on Wednesday, Octo...
GlaxoSmithKline has announced the resignation of one of its Non-Executive Director, Basel Nizameddin. Nizameddin resigned from his position in the com...
The Nigerian stock market closed at 3,252 deals today, Wednesday, July 22, 2020, higher than the 3,500 deals it recorded on Tuesday, July 21, 2020, wh...
GlaxoSmithKline Consumer Nigeria Plc has released it's annual report and financial statements for the year ended December 31, 2019. While the comp...
